about
New Oral Therapies for Psoriasis: A Comprehensive ReviewConsensus Conference on Clinical Management of pediatric Atopic DermatitisThe effects of treatment on itch in atopic dermatitisCutaneous dermatomyositis: an updated review of treatment options and internal associations.A Comparative Study of Oral Cyclosporine and Betamethasone Minipulse Therapy in the Treatment of Alopecia Areata.Acute Kidney Injury Due to Interaction of Methyl-1-testosterone with Ciclosporin Metabolism in a Patient with Severe Atopic Dermatitis.Intralesional therapy for psoriasis.Management of cutaneous dermatomyositis.Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients.Synergism between mTOR pathway and ultraviolet radiation in the pathogenesis of squamous cell carcinoma and its implication for solid-organ transplant recipients.A systematic review of systemic medications for pustular psoriasis in pediatrics.Retrospective review of relapse after systemic cyclosporine in children with atopic dermatitis.Combination therapy of cyclosporine and anti-tumor necrosis factor α in psoriasis: a case series of 10 patients.A clinical audit of high-cost and off-label drug use in dermatology.An Update on Medical Treatment Options for Hidradenitis Suppurativa.The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.Anti-inflammatory effects of intranasal cyclosporine for allergic rhinitis in a mouse model.Anti-IL-17A blocking antibody reduces cyclosporin A-induced relapse in experimental autoimmune encephalomyelitis miceImmune Parameters of Korean Patients with Psoriasis Treated with Low-Dose Cyclosporine.Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome in a Patient with Pemphigus Vulgaris.Therapeutic Efficacy of Combination Therapy Using Oral Cyclosporine with a Dietary Supplement (Pantogar®) in Twenty-Nail Dystrophy.A Patient with Refractory Psoriasis Who Developed Sebaceous Carcinoma on the Neck during Cyclosporine Therapy and Showed Rapid Progression.Estimation of tissue osteopontin levels before and after different traditional therapeutic modalities in psoriatic patients.Proliferative, lymphocytic, infundibular mural folliculitis and dermatitis with prominent follicular apoptosis and parakeratotic casts in four Labrador retrievers: preliminary description and response to therapy.Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis.Production of the immunosuppressant cyclosporin A by a new soil isolate, Aspergillus fumigatus, in submerged culture.Molecular events associated with ciclosporin A-induced gingival overgrowth are attenuated by Smad7 overexpression in fibroblasts.A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis.Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment.
P2860
Q28071475-3DB100DD-4174-4638-AC68-991A8A316066Q28071974-3053C273-6C2E-4C55-8EA8-A929ABA5090CQ34336696-58684F1D-E884-4C6F-93B4-2F303A4DDD82Q34349952-9BB80B2A-06FA-4A1F-9CFB-F534AFCF1783Q37339365-C19CAB68-B85E-4A18-8205-D681CB42C478Q37468345-A1EDC3FB-9CD9-409A-8436-6E412DEB7ADCQ37990555-7D977D55-2762-4372-A963-B7A192B4C665Q38022271-F62E6DAD-66F1-4E0F-A363-B0EAB548D554Q38061479-C6E8D58E-7A70-4ED3-AAE2-330EED3D8C21Q38187197-3DCA6F29-E369-46AB-B19D-8AEB9E02D495Q38217075-561B40EE-2F69-4BA0-B5CD-34FF386DF394Q38233591-69B028ED-D5CE-4661-AE7B-5B4AE23E57BCQ38339763-BB1C9A5D-BC28-4480-9370-49643F824954Q38582166-8C2FF41F-8D33-4F0A-B85A-7F115AC7FC58Q38667207-13522F0A-5085-4BD0-A8B4-8DAE15922648Q38925320-3174DF24-5621-40C1-9598-F3B085FE8C24Q39004668-2537F908-12F9-43AC-8C20-9C1D831EF3EEQ40469419-8213BB00-6BED-476B-9A4B-65E1215B1285Q41682674-3729A548-125E-4B1F-B362-5F6F2A5811DBQ41848258-3A2117A1-0987-4F37-8495-394F1EC3AF60Q42085591-F3F0BDF6-C433-4BD0-A663-ABDF456C8DDEQ42087149-071ADEC8-95A6-4436-942F-84B9AF47A9F6Q42423816-F7EA6D02-DA05-4D61-A4F2-AD4A125A0099Q46029700-891EC4A3-E655-4872-AEFC-5F0909F4D880Q46583154-B4D8D33B-A0A3-48F7-83CA-13CC2EF92A46Q48126820-D6777DDC-3FE4-4DE1-9FE7-B057CAC397A6Q50264644-C4824D0E-46E3-4E69-8D5B-7E0211460F2FQ53222346-FFC3A068-AE84-4FAE-90CF-5346FBDAC798Q53831223-312E8CA9-3EA8-4354-BEAE-459B551DDDC6Q55091628-25921034-41B9-41C5-8523-3FEB9D341F2C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The use of cyclosporine in dermatology: part I.
@en
The use of cyclosporine in dermatology: part I.
@nl
type
label
The use of cyclosporine in dermatology: part I.
@en
The use of cyclosporine in dermatology: part I.
@nl
prefLabel
The use of cyclosporine in dermatology: part I.
@en
The use of cyclosporine in dermatology: part I.
@nl
P1476
The use of cyclosporine in dermatology: part I.
@en
P2093
Alan Menter
Karrie T Amor
P304
925-46; quiz 947-8
P356
10.1016/J.JAAD.2010.02.063
P407
P577
2010-12-01T00:00:00Z